Cedars-Sinai Medical Center | Smidt Heart Institute

Research site

(Unclaimed)

Location

127 S San Vicente Boulevard, A3100, Los Angeles, California, United States of America

Site insights

Top conditions

Top treatments

Pembrolizumab

Belzutifan

Vedolizumab

Atezolizumab

BI 1015550

Elafibranor

Bevacizumab

vincristine

Ipilimumab

doxorubicin

Parent organization

This site is a part of Cedars-Sinai Medical Center

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

72 of 131 total trials

A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy (ACES-EMB)

This is an open label Comparative Effectiveness Research (CER) study in which patients will be randomized at the site level to Prospera surveillance...

Not yet enrolling

Heart Transplant Failure and Rejection

Diagnostic Test: The Prospera™ Test

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitum...

Active, not recruiting

Gastric Cancer

Ovarian Cancer

Drug: CUE-102

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis

ABBV-CLS-7262 is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-part study...

Active, not recruiting

ALS

Amyotrophic Lateral Sclerosis

Drug: Placebo

Drug: ABBV-CLS-7262

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

PART 1: The primary objective of this study is to identify the maximum tolerated dose (MTD) of MK-3795, formerly called PT2385 and/or the recommended...

Active, not recruiting

Kidney Cancer

RCC

Drug: MK-3795

Drug: Nivolumab

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

a Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat (an aldosterone synthase inhibitor), administered on a background of a...

Enrolling

Hypertension

Drug: Placebo

Drug: lorundrostat Dose 2

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Ph...

Invitation-only

Hypertension

Familial Primary Pulmonary Hypertension

Drug: Ralinepag

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combina...

Active, not recruiting

Metastatic Colorectal Cancer

Drug: Inavolisib

Drug: FOLFIRI

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod...

Enrolling

Colitis, Ulcerative

Drug: Ozanimod

A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor

The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combina...

Enrolling

Carcinoma, Hepatocellular

Neoplasms

Drug: Lenvatinib

Drug: E7386

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (AMPLIFY-7P)

This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph...

Enrolling

KRAS G12V

NRAS G12D

Drug: ELI-002 7P

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the...

Active, not recruiting

Neoplasms

Drug: Cetuximab

Drug: Oxaliplatin

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a...

Enrolling

Renal Cell Carcinoma

Drug: HC-7366

Drug: Belzutifan

A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of...

Enrolling

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Drug: Carboplatin

Drug: LY3537982

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (MORPHEUS HR+BC)

This study is designed to evaluate the efficacy, safety, and pharmacokinetics of several immunotherapy-based combination treatments in participants w...

Active, not recruiting

Breast Neoplasms

Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody

Drug: Bevacizumab

A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untr...

Enrolling

Non-small Cell Lung Cancer

Drug: SBRT

Drug: Alectinib

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus t...

Active, not recruiting

Breast Cancer

Drug: 5-Fluorouracil

Drug: Cyclophosphamide

Status recently updated

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor...

Enrolling

Active, not recruiting

Endometrial Cancer

Non-small Cell Carcinoma

Drug: Pembrolizumab

Drug: RGX-104

A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e.,...

Enrolling

Colorectal Carcinoma

KRAS Mutation-Related Tumors

Drug: ompenaclid

Drug: FOLFOX regimen

A Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN)

RADIANCE-HTN is a randomized, double-blind, sham controlled, 2-cohort study (TRIO and SOLO) designed to demonstrate efficacy and document the safety...

Active, not recruiting

Hypertension

Vascular Diseases

Device: Sham Procedure

Device: The Paradise® Renal Denervation Ultrasound System

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab togeth...

Enrolling

Crohn's Disease

Drug: Vedolizumab

Drug: Adalimumab